Results 131 to 140 of about 53,097 (209)

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated.
Surya Ayalasomayajula, Ednan K. Bajwa, Alexandra G. Cornell, Maria Jose Loureiro, Samuel S. Kim, Julia Richmond DiBello, Eric Sterner, Richard Chen, Islam R. Younis   +8 more
wiley   +1 more source

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR‐ABL1 transcript decline velocity in chronic myeloid leukemia: A 16‐year real‐world study

Cancer, Volume 132, Issue 14, 15 July 2026.
Abstract Background No large, randomized trials have compared three or more tyrosine kinase inhibitors (TKIs) in a single chronic myeloid leukemia (CML) cohort. Most studies are two‐arm comparisons versus imatinib, or rely on indirect methods. Methods A retrospective cohort study was conducted of 349 patients with chronic‐ and accelerated‐phase CML ...
Moaath K. Mustafa Ali, Emily C. Zabor, Kamilla Abdurakhmanov, Hadil Zureigat, Ahmed N. Mohamed, Muaz Alsabbagh Alchirazi, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Ameed Bawwab, Bryan Berube, Lana Khatib, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Ronald Sobecks, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee   +21 more
wiley   +1 more source

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications. [PDF]

Future Sci OA
Thompson CM, Andrews MB, Adler DG.
europepmc   +1 more source

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series. [PDF]

Cancer Rep (Hoboken)
Lipplaa A, Hindi N, Teterycz P, Young RJ, Boukonavis I, Cruz J, Martinez-Trufero J, Speetjens F, Peul W, van der Wal RJP, Gelderblom H.   +10 more
europepmc   +1 more source

Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia. [PDF]

Cancer Chemother Pharmacol
Verhagen NE, Touw DCW, van den Heuvel JJMW, van den Broek PH, Blijlevens NMA, Janssen JJWM, Koenderink JB, Russel FGM.   +7 more
europepmc   +1 more source

Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia. [PDF]

J Physiol Biochem
Hrdinova T, Kupcova Skalnikova H.
europepmc   +1 more source

Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>. [PDF]

Oncol Lett
Kroschwald LM, Tauer JT, Kroschwald SI, Suttorp M, Wiedenfeld A, Beissert S, Bauer A, Rauner M.   +7 more
europepmc   +1 more source

Adjuvant Imatinib for Patients Resected for GIST: A Quality Assurance Study. [PDF]

Cancer Med
Mohammad H, Rose HK, Rossen PB, Aggerholm Pedersen N.   +3 more
europepmc   +1 more source

Economic evaluation of ponatinib vs reference and generic imatinib in front-line management of philadelphia chromosome-positive acute lymphoblastic leukemia: A value dilemma. [PDF]

J Manag Care Spec Pharm
Amamoo RS, Schuerman B, Obeng-Kusi M, Yun S, Erstad B, Abraham I.   +5 more
europepmc   +1 more source

Targeting Apoptosis-Resistant Proliferation: Imatinib-Based Combinations Induce Durable Cytostatic Arrest in 3D Endometrial Cancer Spheroids. [PDF]

Biomedicines
Yıldırım B, Biltekin B, Karalök MH, Bilir A.   +3 more
europepmc   +1 more source